L’Oréal SA’s Dermatological struggles intensified in the third quarter due in part to lack of innovation within CeraVe, which dragged on US sales in particular.
L’Oréal Announces ‘Beauty Stimulus’ Plan, CeraVe Product Launches To Bolster Derma Biz
Dermatological Beauty grew only 0.8% in L’Oréal’s third quarter, hampered by US sluggishness attributed in part to lack of innovation in the CeraVe brand. The company announced the launch of two new products that should help to boost the division’s sales in the fourth quarter and reaffirmed confidence in China and L’Oréal’s 2025 prospects.
breaking news
More from Earnings
• By
Coty Inc. reports fiscal second quarter sales slipped 3% on a reported basis to $1.67bn, reflecting further slowing of the mass beauty market, particularly color cosmetics.
• By
L’Oréal Groupe expects total sales in 2025 to beat 4%-4.5% growth anticipated for the overall beauty market, with US population growth, planned innovations boding well across its beauty businesses.
• By
Cincinnati-based P&G reports its antiperspirants/deodorants business is a ‘pocket of strength,’ growing 11% in the US in the fiscal second quarter and helping lift overall beauty sales as skin care stumbles.
New York-based International Flavors & Fragrances, Inc.’s Scent division is undertaking R&D in natural, synthetic chemistry and biotech molecules, says CEO Erik Fyrwald during a third quarter earnings presentation 6 November.
More from HBW Insight
• By
Vitawell seeking to empower consumers left confused by the vast array of dietary supplements available to them in the UK.
• By
Tariffs on imports from China and look at eliminating self-affirmed GRAS pathway introduced under Trump while DoJ Consumer Protection Branch also continues supplement sector priorities enduring across administrations.
• By
Round up of the latest appointments: PAGB names vice presidents; Activ'Inside gets first US head; EMA elects management board chair.